Effects of additive therapy of losaretan in chronic obstructive pulmonary disease
Phase 2
- Conditions
- chronic obstructive pulmonary disease.Other chronic obstructive pulmonary disease
- Registration Number
- IRCT201103166080N1
- Lead Sponsor
- Arak university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
history of chronic obstructive lung disease base on spirometry data and clinical sign and symptoms referred by pulmonologist. Exclusion criteria: congestive heart failure; myocardial infarction in 6 months ego; consumption of angiotensine converting enzyme inhibitors and angiotensine receptor blockers; dehydration; renal artery stenosis; hyperkalemia; uncontrolled hypertension; allergy to losaretan.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FVC-percent of forced vital capacity. Timepoint: 4months. Method of measurement: By spirometer.;FEV1—Forced expiratory volume in one second percent of. Timepoint: 4 month. Method of measurement: By spirometr.;Hematocrit. Timepoint: 4 month. Method of measurement: Percent and by coulter sysmex.;Fev1/fvc. Timepoint: 4 months. Method of measurement: By spirometer.;FEF25%-75%. Timepoint: 4months. Method of measurement: By spirometer.;Severity of dyspnea. Timepoint: 4 months. Method of measurement: Grade and by modified medical research council-MMRC Scale.
- Secondary Outcome Measures
Name Time Method Raising of creatinine. Timepoint: 1 month. Method of measurement: laboratory.